Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings yield is N/A as of 2026-10-06T19:59:06.501Z.
Calculation as of: 2026-10-06T19:59:06.501Z.
Quote observation: 2026-10-06T19:55:23.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: bc1f4c18f19876ab16fbc38bb33c2f59d02ebf5b777874ee4386cd5e587f8fe3
EARNINGS YIELD
N/A
Market Cap
$632.24M
Earnings Yield
8.70%
TTM Avg
11.77%
3Y Avg
11.77%
5Y Avg
9.40%
Market Cap
$597.55M
Earnings Yield
21.13%
TTM Avg
9.68%
3Y Avg
7.09%
5Y Avg
13.06%
Market Cap
$656.40M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EARNINGS YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SOPHiA GENETICS S.A. (SOPH) | $626.70M | N/A | N/A | N/A | N/A |
| OmniAb, Inc. (OABI)vs › | $622.66M | N/A | N/A | N/A | N/A |
| Zevra Therapeutics, Inc. (ZVRA)vs › | $632.24M | 8.70% | 11.77% | 11.77% | 9.40% |
| Prime Medicine, Inc. (PRME)vs › | $636.68M | N/A | N/A | N/A | N/A |
| Aura Biosciences, Inc. (AURA)vs › | $638.20M | N/A | N/A | N/A | N/A |
| Climb Bio, Inc. (CLYM)vs › | $611.00M | N/A | N/A | N/A | N/A |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $597.55M | 21.13% | 9.68% | 7.09% | 13.06% |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $656.40M | N/A | N/A | N/A | N/A |
| Starling Oncology, Inc. (STLN)vs › | $656.89M | N/A | N/A | N/A | N/A |
| Annexon, Inc. (ANNX)vs › | $660.29M | N/A | N/A | N/A | N/A |
Earnings Yield
N/A
EPS ÷ Price
P/E Ratio
N/A
Price ÷ EPS
Formula: Earnings Yield = (EPS / Price) × 100
Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.
How earnings yield is used:
Earnings Yield = EPS (TTM) / Share Price
Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
